TY - JOUR
TI - Ovarian Cancer and Body Size: Individual Participant Meta-Analysis
Including 25,157 Women with Ovarian Cancer from 47 Epidemiological
Studies
AU - Beral, V.
AU - Hermon, C.
AU - Peto, R.
AU - Reeves, G.
AU - Brinton, L. and
AU - Marchbanks, P.
AU - Negri, E.
AU - Ness, R.
AU - Peeters, P. H. M. and
AU - Vessey, M.
AU - Calle, E. E.
AU - Gapstur, S. M.
AU - Patel, A. V.
AU - Dal
AU - Maso, L.
AU - Talamini, R.
AU - Chetrit, A.
AU - Hirsh-Yechezkel, G. and
AU - Lubin, F.
AU - Sadetzki, S.
AU - Allen, N.
AU - Bull, D.
AU - Callaghan, K.
AU - and Crossley, B.
AU - Gaitskell, K.
AU - Goodill, A.
AU - Green, J. and
AU - Key, T.
AU - Moser, K.
AU - Collins, R.
AU - Doll, R.
AU - Gonzalez, C. A.
AU - and Lee, N.
AU - Ory, H. W.
AU - Peterson, H. B.
AU - Wingo, P. A. and
AU - Martin, N.
AU - Pardthaisong, T.
AU - Silpisornkosol, S.
AU - Theetranont,
AU - C.
AU - Boosiri, B.
AU - Chutivongse, S.
AU - Jimakorn, P.
AU - Virutamasen,
AU - P.
AU - Wongsrichanalai, C.
AU - Tjonneland, A.
AU - Titus-Ernstoff, L. and
AU - Byers, T.
AU - Rohan, T.
AU - Mosgaard, B. J.
AU - Yeates, D. and
AU - Freudenheim, J. L.
AU - Chang-Claude, J.
AU - Kaaks, R.
AU - Anderson, K.
AU - E.
AU - Folsom, A.
AU - Robien, K.
AU - Rossing, M. A.
AU - Thomas, D. B.
AU - and Weiss, N. S.
AU - Riboli, E.
AU - Clavel-Chapelon, F.
AU - Cramer, D.
AU - and Hankinson, S. E.
AU - Tworoger, S. S.
AU - Franceschi, S.
AU - La
AU - Vecchia, C.
AU - Magnusson, C.
AU - Riman, T.
AU - Weiderpass, E.
AU - Wolk,
AU - A.
AU - Schouten, L. J.
AU - van den Brandt, P. A.
AU - Chantarakul, N. and
AU - Koetsawang, S.
AU - Rachawat, D.
AU - Palli, D.
AU - Black, A.
AU - de
AU - Gonzalez, A. Berrington
AU - Freedman, D. M.
AU - Hartge, P.
AU - Hsing, A.
AU - W.
AU - Lacey, Jr., J. V.
AU - Hoover, R. N.
AU - Schairer, C. and
AU - Graff-Iversen, S.
AU - Selmer, R.
AU - Bain, C. J.
AU - Green, A. C. and
AU - Purdie, D. M.
AU - Siskind, V.
AU - Webb, P. M.
AU - McCann, S. E. and
AU - Hannaford, P.
AU - Kay, C.
AU - Binns, C. W.
AU - Lee, A. H.
AU - Zhang, M.
AU - and Ness, R. B.
AU - Nasca, P.
AU - Coogan, P. F.
AU - Palmer, J. R. and
AU - Rosenberg, L.
AU - Kelsey, J.
AU - Paffenbarger, R.
AU - Whittemore, A. and
AU - Katsouyanni, K.
AU - Trichopoulou, A.
AU - Trichopoulos, D.
AU - Tzonou, A.
AU - and Dabancens, A.
AU - Martinez, L.
AU - Molina, R.
AU - Salas, O. and
AU - Goodman, M. T.
AU - Lurie, G.
AU - Carney, M. E.
AU - Wilkens, L. R. and
AU - Hartman, L.
AU - Manjer, J.
AU - Olsson, H.
AU - Grisso, J. A.
AU - Morgan,
AU - M.
AU - Wheeler, J. E.
AU - Casagrande, J.
AU - Pike, M. C.
AU - Ross, R. K.
AU - and Wu, A. H.
AU - Miller, A. B.
AU - Kumle, M.
AU - Lund, E.
AU - McGowan,
AU - L.
AU - Shu, X. O.
AU - Zheng, W.
AU - Farley, T. M. M.
AU - Holck, S. and
AU - Meirik, O.
AU - Risch, H. A.
AU - Collaborative Grp Epidemiol Studie
JO - PLoS Medicine
PY - 2012
VL - 9
TODO - 4
SP - null
PB - Public Library of Science
SN - 1549-1277, 1549-1676
TODO - 10.1371/journal.pmed.1001200
TODO - null
TODO - Background: Only about half the studies that have collected information
on the relevance of women’s height and body mass index to their risk of
developing ovarian cancer have published their results, and findings are
inconsistent. Here, we bring together the worldwide evidence, published
and unpublished, and describe these relationships.
Methods and Findings: Individual data on 25,157 women with ovarian
cancer and 81,311 women without ovarian cancer from 47 epidemiological
studies were collected, checked, and analysed centrally. Adjusted
relative risks of ovarian cancer were calculated, by height and by body
mass index. Ovarian cancer risk increased significantly with height and
with body mass index, except in studies using hospital controls. For
other study designs, the relative risk of ovarian cancer per 5 cm
increase in height was 1.07 (95% confidence interval [CI], 1.05-1.09;
p<0.001); this relationship did not vary significantly by women’s age,
year of birth, education, age at menarche, parity, menopausal status,
smoking, alcohol consumption, having had a hysterectomy, having first
degree relatives with ovarian or breast cancer, use of oral
contraceptives, or use of menopausal hormone therapy. For body mass
index, there was significant heterogeneity (p<0.001) in the findings
between ever-users and never-users of menopausal hormone therapy, but
not by the 11 other factors listed above. The relative risk for ovarian
cancer per 5 kg/m(2) increase in body mass index was 1.10 (95% CI,
1.07-1.13; p<0.001) in never-users and 0.95 (95% CI, 0.92-0.99; p =
0.02) in ever-users of hormone therapy.
Conclusions: Ovarian cancer is associated with height and, among
never-users of hormone therapy, with body mass index. In high-income
countries, both height and body mass index have been increasing in birth
cohorts now developing the disease. If all other relevant factors had
remained constant, then these increases in height and weight would be
associated with a 3% increase in ovarian cancer incidence per decade.
ER -